Orthofuse secures £2.2m in seed funding to advance 3D-printed surgical implants.
The round was led by a group of angel investors to support technical development and regulatory readiness.
Share allotment filed at Companies House
Orthofuse develops advanced 3D-printed orthopaedic implants designed to improve manoeuvrability and reversibility for surgeons.
London-based medtech startup Orthofuse has secured £2.2m in a seed round led by a group of angel investors. The financing also saw participation from ACF Investors, Cambridge Angels, and Empirical Ventures.
The capital will be directed towards technical development, regulatory preparation, and building partnerships ahead of early-stage clinical evaluations. Orthofuse focuses on tackling inefficiencies in complex trauma and spinal surgery through smarter, 3D-printed implant systems.
The company aims to simplify procedures and reduce surgical times by offering hardware that surgeons can adjust or reposition without damaging surrounding tissue.
From the founder
"The main pain point here is that orthopaedic trauma and spinal degenerative conditions are technically demanding, time-sensitive, and extremely challenging when there is poor bone quality. Current implant systems struggle to comprehensively meet the needs of the patient and the surgeon. The inherent limitations cause prolonged surgical times and increased risks to the patient."
James Scott
CEO and Co-Founder at Orthofuse
Investor perspective
"Orthofuse has reimagined the fundamental architecture of implants to solve the inefficiencies of current solutions. We believe this approach has real value in improving orthopaedic care, and are pleased to support the team as they move forward."
Didier Cowling
Partner, Oshen Holdings
Use of funds
- 01Fund research and development
- 02Fund the next phase of growth
